404 related articles for article (PubMed ID: 17569869)
1. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.
Ohto U; Fukase K; Miyake K; Satow Y
Science; 2007 Jun; 316(5831):1632-4. PubMed ID: 17569869
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2.
Ohto U; Fukase K; Miyake K; Shimizu T
Proc Natl Acad Sci U S A; 2012 May; 109(19):7421-6. PubMed ID: 22532668
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of mouse MD-1 with endogenous phospholipid bound in its cavity.
Harada H; Ohto U; Satow Y
J Mol Biol; 2010 Jul; 400(4):838-46. PubMed ID: 20595044
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO
Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912
[TBL] [Abstract][Full Text] [Related]
5. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization.
Saitoh S; Akashi S; Yamada T; Tanimura N; Kobayashi M; Konno K; Matsumoto F; Fukase K; Kusumoto S; Nagai Y; Kusumoto Y; Kosugi A; Miyake K
Int Immunol; 2004 Jul; 16(7):961-9. PubMed ID: 15184344
[TBL] [Abstract][Full Text] [Related]
6. Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4.
Zimmer SM; Zughaier SM; Tzeng YL; Stephens DS
Glycobiology; 2007 Aug; 17(8):847-56. PubMed ID: 17545685
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of soluble MD-1 and its interaction with lipid IVa.
Yoon SI; Hong M; Han GW; Wilson IA
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):10990-5. PubMed ID: 20534476
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of non-specific lipid binding in maize lipid-transfer protein complexes revealed by high-resolution X-ray crystallography.
Han GW; Lee JY; Song HK; Chang C; Min K; Moon J; Shin DH; Kopka ML; Sawaya MR; Yuan HS; Kim TD; Choe J; Lim D; Moon HJ; Suh SW
J Mol Biol; 2001 Apr; 308(2):263-78. PubMed ID: 11327766
[TBL] [Abstract][Full Text] [Related]
9. Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions.
Resman N; Oblak A; Gioannini TL; Weiss JP; Jerala R
J Immunol; 2014 Feb; 192(4):1887-95. PubMed ID: 24420921
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli.
Kohara J; Tsuneyoshi N; Gauchat JF; Kimoto M; Fukudome K
Protein Expr Purif; 2006 Oct; 49(2):276-83. PubMed ID: 16839777
[TBL] [Abstract][Full Text] [Related]
11. Two modes of ligand recognition by TLRs.
Brodsky I; Medzhitov R
Cell; 2007 Sep; 130(6):979-81. PubMed ID: 17889640
[TBL] [Abstract][Full Text] [Related]
12. Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa.
Muroi M; Tanamoto K
J Biol Chem; 2006 Mar; 281(9):5484-91. PubMed ID: 16407172
[TBL] [Abstract][Full Text] [Related]
13. Immunology. The shape of things to come.
Fitzgerald KA; Golenbock DT
Science; 2007 Jun; 316(5831):1574-6. PubMed ID: 17569850
[No Abstract] [Full Text] [Related]
14. Lipid A from lipopolysaccharide recognition: structure, dynamics and cooperativity by molecular dynamics simulations.
Garate JA; Oostenbrink C
Proteins; 2013 Apr; 81(4):658-74. PubMed ID: 23184816
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVa.
Walsh C; Gangloff M; Monie T; Smyth T; Wei B; McKinley TJ; Maskell D; Gay N; Bryant C
J Immunol; 2008 Jul; 181(2):1245-54. PubMed ID: 18606678
[TBL] [Abstract][Full Text] [Related]
16. Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces.
Maeshima N; Evans-Atkinson T; Hajjar AM; Fernandez RC
J Biol Chem; 2015 May; 290(21):13440-53. PubMed ID: 25837248
[TBL] [Abstract][Full Text] [Related]
17. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold.
Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A
Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of mouse and human RP105/MD-1 complexes reveal unique dimer organization of the toll-like receptor family.
Ohto U; Miyake K; Shimizu T
J Mol Biol; 2011 Nov; 413(4):815-25. PubMed ID: 21959264
[TBL] [Abstract][Full Text] [Related]
19. MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA.
Meng J; Drolet JR; Monks BG; Golenbock DT
J Biol Chem; 2010 Sep; 285(36):27935-43. PubMed ID: 20592019
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids.
Fujiwara S; Amisaki T
Proteins; 2006 Aug; 64(3):730-9. PubMed ID: 16783783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
